BMS’s Cancer Trial Showcases Potential for Checkpoint Inhibitors
Bristol Myers Squibb’s recent phase III success provided the first late-stage confirmation for a novel…
Bristol Myers Squibb’s recent phase III success provided the first late-stage confirmation for a novel…
European biotech companies are flocking to the Nasdaq Stock Market in 2020, but not all…
Here are the most innovative therapies presented by European biotechs fighting cancer during the ASCO…
The unprecedented competition in the field represents a daunting challenge for companies trying to break…
Before the “who to recruit” phase, an important question is “where?” We ran through the…
While some might accuse the field of being over-hyped, immuno-oncology continues to attract attention and investment for…
Cambridge's image is tied to its Hogwarts-like University and Nobel-hoarding academia, but there's also an…
The series of profiles on impressive biotech leaders continues: John Haurum founded one of the…
Biotech is one of the main forces driving the development of effective therapies to treat neurological and…
Imagine a conference where all the Biotech CEOs and investors of the World come together...all…
This year has started with a rush of deals for many Biotechs. F-Star another such…
Second interview of BIO-Europe 2015. This time, it's a British company from Cambridge (UK): F-star.…